ライフサイエンスコーパス: partial thromboplastin time

1 ad no effect on the TF-independent activated partial thromboplastin time.

2 , platelets, prothrombin time, and activated partial thromboplastin time.

3 time and, at higher doses, of the activated partial thromboplastin time.

4 tithrombin III, platelet count, or activated partial thromboplastin time.

5 y and a marked prolongation of the activated partial thromboplastin time.

6 nogen level, prothrombin time, and activated partial thromboplastin time.

7 gatroban, adjusted to maintain the activated partial thromboplastin time 1.5 to 3.0 times baseline va

8 og x kg x min, adjusted to achieve activated partial thromboplastin times 1.5-3 times baseline

9 ng victims had a three-fold longer activated partial thromboplastin time (124 s; p<0.001) than both n

10 doses of heparin (n = 50) (target activated partial thromboplastin time, 65 to 90 seconds or 90 to 1

11 cytopenia (13% and 23%); prolonged activated partial thromboplastin time (8% and 18%); elevated aspar

12 mbin generation, prothrombin time, activated partial thromboplastin time, activated clotting time, an

13 es in thrombin generation, prothrombin time, partial thromboplastin time, activated clotting time, R+

14 No relationship was seen with activated partial thromboplastin time, activated protein C resista

15 -factor Xa activity but comparable activated partial thromboplastin time activity.

16 profiles (index normalized ratio, activated partial thromboplastin time) after reperfusion were simi

17 These functional studies and activated partial thromboplastin time analysis validate prediction

18 e eliminating more than 90% of its activated partial thromboplastin time and anti-factor Xa activity.

19 t pathway components prolonged the activated partial thromboplastin time and decreased target protein

20 but was associated with prolonged activated partial thromboplastin time and extravascular hemorrhage

21 ion between the peak posttreatment activated partial thromboplastin time and post hoc weight-adjusted

22 the permissive range and returned activated partial thromboplastin time and prothrombin time clottin

23 Plasma activated partial thromboplastin time and prothrombin time increas

24 Activated partial thromboplastin time and prothrombin time were sh

25 ability of heparin to prolong the activated partial thromboplastin time and the factor Xa- one-stage

26 Klkb1(-/-) plasmas have long-activated partial thromboplastin times and defective contact activ

27 Coagulation was assessed using activated partial thromboplastin times and prothrombin times.

28 vels and increased prothrombin and activated partial thromboplastin times and tissue factor, tissue f

29 ssays of thrombosis in vitro (e.g. activated partial thromboplastin time) and in vivo (e.g. rat FeCl(

30 ts, fibrinogen, prothrombin index, activated partial thromboplastin time, and d-dimer as well as the

31 high D-dimer, prolonged prothrombin time and partial thromboplastin time, and falling fibrinogen) res

32 platelets and increases of prothrombin time, partial thromboplastin time, and fibrin split products.

33 count, bleeding, fibrinogen level, activated partial thromboplastin time, and somnolence.

34 f the activated clotting time, the activated partial thromboplastin time, and the cuticle bleeding ti

35 ant effect as assessed by anti-Xa, activated partial thromboplastin time (aPTT) and activated clottin

36 The activated partial thromboplastin time (aPTT) and anti-factor X (an

37 The activated partial thromboplastin time (APTT) and prothrombin time

38 Activated partial thromboplastin time (aPTT) and prothrombin time

39 FIX21D had reduced activity in an activated partial thromboplastin time (aPTT) assay and was activat

40 has relatively normal activity in activated partial thromboplastin time (aPTT) assays.

41 arin group without prolongation of activated partial thromboplastin time (aPTT) before and after the

42 ctivity as measured by a one-stage activated partial thromboplastin time (aPTT) clotting assay (36% +

43 C mutants were characterized using activated partial thromboplastin time (APTT) clotting assays and F

44 Finally, the activated partial thromboplastin time (aPTT) coagulation assay was

45 We examined the activated partial thromboplastin time (aPTT) in 29,656 patients in

46 ponse to infusion of thrombin, the activated partial thromboplastin time (APTT) increased by 11+/-3 s

47 Reduced activated partial thromboplastin time (aPTT) is a risk marker for

48 Activated partial thromboplastin time (aPTT) is associated with ri

49 rolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT) obtained before elect

50 th short prothrombin time (PT) and activated partial thromboplastin time (APTT) of 14.2 and 35.5s res

51 hrombins were titrated to a target activated partial thromboplastin time (aPTT) of 55 to 85 seconds a

52 s, frozen thawed washed platelets, activated partial thromboplastin time (aPTT) reagent and prothromb

53 easure the clotting time using the activated partial thromboplastin time (APTT) test.

54 Site-specific validation of the activated partial thromboplastin time (aPTT) therapeutic range is

55 ational normalized ratio (INR) and activated partial thromboplastin time (aPTT) values were 1.5 and 4

56 Additional association with activated partial thromboplastin time (aPTT) was tested for the to

57 ong both the thrombin time and the activated partial thromboplastin time (aPTT) when added to normal

58 lted in complete correction of the activated partial thromboplastin time (aPTT), and that injection o

59 (dTT), ecarin clotting time (ECT), activated partial thromboplastin time (aPTT), and thrombin time (T

60 Increases in activated partial thromboplastin time (aPTT), anti-factors IIa and

61 ite activated clotting time (ACT), activated partial thromboplastin time (APTT), heparin concentratio

62 onding CCTs [prothrombin time (PT)/activated partial thromboplastin time (aPTT), international normal

63 We tested the activated partial thromboplastin time (APTT), international normal

64 ignificant 43% prolongation of the activated partial thromboplastin time (aPTT), over controls (P < 0

65 We measured ACT (Hemochron), activated partial thromboplastin time (aPTT), plasma anti-Xa and a

66 in at doses that significantly prolonged the partial thromboplastin time (APTT), prothrombin time (PT

67 ent than ATS-112 in prolonging the activated partial thromboplastin time (APTT), whereas ATS-119 inhi

68 frequently combined with tests for activated partial thromboplastin time (aPTT).

69 tivated coagulation time (ACT) and activated partial thromboplastin time (aPTT).

70 ity) and a concomitant increase in activated partial thromboplastin time (APTT).

71 The activated partial thromboplastin time (APTT; baseline, 28 seconds)

72 resistance ratio values (ratio of activated partial thromboplastin time [APTT] clotting times with a

73 activated clotting time [ACT], and activated partial thromboplastin time [aPTT]) have remained at the

74 while the acoustic assays namely ''activated Partial Thromboplastin Time'' (aPTT) and ''Prothrombinas

75 fewer than 35% of patients having activated partial thromboplastin times (aPTTs) within a range of 5

76 nomogram with centrally monitored activated partial thromboplastin times (aPTTs).

77 n factor XI deficient plasma in an activated partial thromboplastin time assay, with a specific activ

78 uction in specific activity in the activated partial thromboplastin time assay.

79 prolonged the clotting time in an activated partial thromboplastin time assay.

80 stern blots, prothrombin time, and activated partial thromboplastin time assays and fibrinopeptide A

81 otein C (APC) cofactor activity in activated partial thromboplastin time assays in PS-depleted plasma

82 ng activity in modified prothrombin time and partial thromboplastin time assays, respectively.

83 2%, 53%, and <5%, respectively, in activated partial thromboplastin time assays.

84 ctive in both prothrombin time and activated partial thromboplastin time assays; however, it exhibite

85 time dose dependently; the median activated partial thromboplastin time at 10 minutes after a single

86 oubled activated clotting time and activated partial thromboplastin time at the higher dose.

87 reated FV was analyzed in an aPTT (activated partial thromboplastin time)-based APC sensitivity assay

88 r = 0.47, P = 0.035), but not with activated partial thromboplastin time-based APC resistance ratios.

89 reover, fibrinogen, platelets, and activated partial thromboplastin time (but not prothrombin index)

90 ane bound TF, and has no effect on activated partial thromboplastin time, but is 70-fold less potent

91 as measured in a factor VIII-based activated partial thromboplastin time clot assay.

92 tectable anticoagulant activity in activated partial thromboplastin time clotting assays but retained

93 In activated partial thromboplastin time clotting assays, the specifi

94 ements of laboratory-based prothrombin time, partial thromboplastin time, complete blood count, and b

95 with impaired liver function, and activated partial thromboplastin time confounding may interfere wi

96 ned bleeding time, decreased prothrombin and partial thromboplastin times (decreased plasma clotting

97 Patients with prolonged partial thromboplastin times did not have a statisticall

98 RB006 increased the activated partial thromboplastin time dose dependently; the median

99 The activated partial thromboplastin time, factor VIII activity, von-W

100 atelet counts, with plasma prothrombin time, partial thromboplastin time, fibrinogen levels, fibrin s

101 rs by changes in prothrombin time, activated partial thromboplastin time, fibrinogen, fibrinogen-fibr

102 In contrast, activated partial thromboplastin time for 7.5% NaCl adenocaine/Mg(

103 cyte count (five [12%]), prolonged activated partial thromboplastin time (four [10%]), and decreased

104 ated patients achieved therapeutic activated partial thromboplastin times generally within 4 to 5 hou

105 Longer activated partial thromboplastin time (hazards ratio, 0.98; p = 0.

106 to explain the prolongation of the activated partial thromboplastin time identified in patients with

107 gation of the prothrombin time and activated partial thromboplastin time in affected individuals.

108 mpound 32 caused a doubling of the activated partial thromboplastin time in human plasma at 2.4 micro

109 onucleotides (PS ODNs) prolong the activated partial thromboplastin time in human plasma by inhibitio

110 Test performance characteristics for the partial thromboplastin time in predicting postoperative

111 Prolongation of activated partial thromboplastin time in streptococcal toxic shock

112 ed lymphocyte count, and prolonged activated partial thromboplastin time in the soft-tissue sarcoma g

113 ncreases both prothrombin time and activated partial thromboplastin time in vitro or ex vivo.

114 thesis, prolonged prothrombin, and activated partial thromboplastin times, in whom no classifying dia

115 se) and coagulation times (prothrombin time, partial thromboplastin time) indicated that iNO improved

116 lly if the baseline (pretreatment) activated partial thromboplastin time is prolonged.

117 eutic bivalirudin anticoagulation (activated partial thromboplastin time less than twice the control

118 00, 500, or 2500 units/kg produced activated partial thromboplastin time levels less than, within, or

119 sorium, low serum albumin concentration, and partial thromboplastin time < or =25 seconds predict a h

120 sorium, low serum albumin concentration, and partial thromboplastin time < or =25 seconds.

121 to sepsis, heparin titrated using activated partial thromboplastin times may be efficacious.

122 or alpha-2-macroglobulin (A2M) and activated partial thromboplastin time measurement for coagulation

123 macodynamic response, reflected in activated partial thromboplastin time measurements, was seen after

124 tients) that compared therapeutic (activated partial thromboplastin time more than twice the control

125 international normalized ratio of 1.2, and a partial thromboplastin time of 29.3 seconds.

126 atory studies revealed a prolonged activated partial thromboplastin time of 49.2 seconds, a normal pr

127 15H8 prolonged the activated partial thromboplastin time of baboon and human plasmas.

128 The activated partial thromboplastin time of the treated mice was full

129 /kg with E. coli further increased activated partial thromboplastin time (p < .0001 vs. placebo) with

130 ), prothrombin time (p < .02), and activated partial thromboplastin time (p < .05).

131 (i.e., with placebo) increased the activated partial thromboplastin time (p = .002) close to the ther

132 Severe activated partial thromboplastin time prolongation may be a marker

133 Grade I post-partial thromboplastin time prolongations were noted.

134 (p < 0.05, respectively), and the activated partial thromboplastin time prolonged significantly at 2

135 Mean activated partial thromboplastin time, prothrombin time, and inter

136 changes in the prothrombin time (PT) and the partial thromboplastin time (PTT) in response to the fir

137 Ocular examinations, virus isolation, and partial thromboplastin time (PTT) were evaluated during

138 evere injury, prolonged prothrombin time and partial thromboplastin time (PTT), and lower levels of b

139 Prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen/fibrin deg

140 ective, linear prolongation of the activated partial thromboplastin time (PTT).

141 ed ratio (r=0.72) but less so with activated partial thromboplastin time (r=0.56; all P<0.001).

142 en the dose of heparin was decreased and the partial thromboplastin time returned towards the normal

143 minogen activator inhibitor 1, and activated partial thromboplastin time showed variability but no si

144 The treated mice exhibited activated partial thromboplastin times that were comparable to tho

145 and APC-dependent prolongation of activated partial thromboplastin times that were two- to three-fol

146 d prolonged prothrombin time to 113% +/- 2%, partial thromboplastin time to 122% +/- 4%, activated cl

147 RB007 reversed the activated partial thromboplastin time to baseline levels within a

148 se levels) and sustained return of activated partial thromboplastin time to within the normal range.

149 L, fibrinogen level <60 mg/dL, and activated partial thromboplastin time values >100 seconds were the

150 At 60-min resuscitation, activated partial thromboplastin time values for untreated, 7.5% N

151 se cases were associated with subtherapeutic partial thromboplastin time values.

152 Baseline plasma activated partial thromboplastin time was 17+/-0.5 secs and increa

153 the mean dose was 588 units/hr, and the mean partial thromboplastin time was 37 secs.

154 nificant, dose-related increase in activated partial thromboplastin time was accompanied by a trend t

155 Prolongation of activated partial thromboplastin time was associated with reduced

156 o gamma-thrombin was inhibited and activated partial thromboplastin time was increased after treatmen

157 Partial thromboplastin time was increased six- to sevenf

158 The activated partial thromboplastin time was prolonged in only the rT

159 The activated partial thromboplastin time was prolonged to a similar e

160 The activated partial thromboplastin time was unchanged.

161 Prolongation of prothrombin and partial thromboplastin times was accompanied by evidence

162 asma and both prothrombin time and activated partial thromboplastin time were normal.

163 levels were normal, but prothrombin time and partial thromboplastin time were prolonged and bone alka

164 Lower values for Quick's test and higher partial thromboplastin times were associated with a high

165 Systemic partial thromboplastin times were not affected by local

166 ncentrations and increase in prothrombin and partial thromboplastin times were significantly attenuat

167 ococcal necrotizing fasciitis, the activated partial thromboplastin times were significantly prolonge

168 od clotting times were normalized, activated partial thromboplastin times were substantially reduced,

169 lot formation time, T(GP), and the activated partial thromboplastin time, whereas the association of